|Bid||137.03 x 800|
|Ask||137.11 x 800|
|Day's Range||134.75 - 137.99|
|52 Week Range||118.62 - 148.32|
|Beta (3Y Monthly)||0.53|
|PE Ratio (TTM)||271.17|
|Earnings Date||Oct 16, 2018|
|Forward Dividend & Yield||3.60 (2.69%)|
|1y Target Est||144.53|
Netflix earnings on Tuesday will be the day's main event with Goldman Sachs, IBM, Morgan Stanley, and Johnson & Johnson also reporting results in a busy day for corporate news.
posted solid third quarter earnings Tuesday, and boosted its full-year profit guidance, thanks in part to a stronger-than-expected performance for key cancer treatments that offset fading sales for Remicade, its blockbuster arthritis drug. Group sales rose 2% to $20.3 billion, the company said, again topping the consensus estimate thanks to better-than-expected sales for cancer drugs Zytiga and Darzalex. The group sees adjusted 2018 earnings per share to be in the range of $8.13 and $8.18 per share, a few cents higher -- at the lower end -- from the previous forecasts.
Shares were unchanged in premarket trading, with the company forecasting adjusted 2018 earnings per share in the range of $8.13 and $8.18, marginally up from a previous range of $8.07 to $8.17. "This is exactly how we want to start the third earnings season," BMO Capital Markets analyst Joanne Wuensch wrote in a note, referring to the overall sales number. As Remicade faces increased competition and sales of medical devices and some consumer products weaken, J&J has been relying on its new cancer drugs as well as deals like the $30 billion purchase of rare disease specialist Actelion last year.
Johnson & Johnson reported slightly better-than-expected quarterly profit on Tuesday and pushed its full-year forecast higher, as demand for its cancer drugs Zytiga and Imbruvica helped offset falling sales of arthritis treatment Remicade. Shares were unchanged in premarket trading, with the company forecasting adjusted 2018 earnings per share in the range of $8.13 and $8.18, marginally up from a previous range of $8.07 to $8.17. "This is exactly how we want to start the third earnings season," BMO Capital Markets analyst Joanne Wuensch wrote in a note, referring to the overall sales number.
World stock markets are turning higher again Tuesday, helped by strong earnings reports from major U.S. companies. Investment banks Morgan Stanley and Goldman Sachs, health care products company Johnson ...
Johnson & Johnson applauded a U.S. government proposal requiring drugmakers to include price of medicines in television ads, Chief Financial Officer Joseph Wolk said in a CNBC interview on Tuesday. The ...
The Dow Jones Industrial Average rose sharply on Tuesday. Click here to register for a free online video in which TheStreet's retirement expert Robert Powell and an all-star panel run down all you need to know.
Of the 30 Dow Jones Industrial Average components, 29 are trading higher in the premarket, with the three that reported third-quarter earnings accounting for nearly a half of the gains in Dow futures . Of the other reporters, shares of UnitedHealth Group Inc. climbed 3.2%, Goldman Sachs Group Inc. rose 2.2% and Johnson & Johnson gained 0.4%. The stocks' price gains are adding about a combined 92 points to the Dow's price, and futures are up 227 points. The most active Dow stock was Apple Inc.'s , which rose 0.9%. The lone Dow decliner Coca-Cola Co.'s stock , which lost 0.6%.
Here are some of the companies with shares expected to trade actively in Tuesday’s session. Stock movements noted by ticker reflect movements during regular trading hours; premarket trading is specified separately.
China stocks fall into bear market territory ahead of Friday's Q3 GDP release amid persist concern that its U.S. trade war will harm second half growth. U.S. stocks called higher, with the Dow slated for a 160 point gains thanks to solid earnings from Morgan Stanley, Goldman Sachs and Johnson & Johnson.
J&J said it now expects sales for the year to be between $81 billion and $81.4 billion, above its previous guidance of $80.5 billion to $81.3 billion. J&J’s third-quarter sales rose 3.6% from a year ago to $20.35 billion. Sales in the pharmaceuticals division in the U.S. rose 4.8% while J&J’s consumer segment sales rose 6.6%.
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 0.99% and 2.19%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Check out the companies making headlines before the bell: Morgan Stanley MS – The investment firm beat estimates by 16 cents a share , with quarterly earnings of $1.17 per share. Revenue came in above forecasts, as well.